207 related articles for article (PubMed ID: 10668939)
21. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?
Schwaibold H; Pichlmeier U; Klingenberger HJ; Huland H
Eur Urol; 1997; 31(2):153-9. PubMed ID: 9076457
[TBL] [Abstract][Full Text] [Related]
23. Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer.
Mostafid AH; Rajkumar RG; Stewart AB; Singh R
BJU Int; 2006 Mar; 97(3):509-12. PubMed ID: 16469017
[TBL] [Abstract][Full Text] [Related]
24. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial.
Di Stasi SM; Valenti M; Verri C; Liberati E; Giurioli A; Leprini G; Masedu F; Ricci AR; Micali F; Vespasiani G
Lancet Oncol; 2011 Sep; 12(9):871-9. PubMed ID: 21831711
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy: Electromotive mitomycin in superficial bladder cancer.
Oosterlinck W
Nat Rev Clin Oncol; 2011 Sep; 8(11):633-4. PubMed ID: 21912417
[No Abstract] [Full Text] [Related]
26. Histological changes due to intravesical instillation of mitomycin C.
Castillo OA; Landerer E; Feria-Flores M; Vidal-Mora I; Franco C
Arch Esp Urol; 2012 Jun; 65(5):578-82; discussion 582. PubMed ID: 22732786
[TBL] [Abstract][Full Text] [Related]
27. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?
Altay B; Girgin C; Kefi A; Cikili N
Int Urol Nephrol; 2000; 32(1):53-8. PubMed ID: 11057773
[TBL] [Abstract][Full Text] [Related]
28. [Long-term effects on recurrence and mortality in superficial urothelioma of the bladder treated with endovesical chemotherapy].
Ferraris V; Serao A; Buffa G
Minerva Urol Nefrol; 1999 Jun; 51(2):95-101. PubMed ID: 10429419
[TBL] [Abstract][Full Text] [Related]
29. Incrusted cystitis after intravesical mitomycin C treatment.
Llopis M; Moreno J; Botella R; Algado M
Acta Urol Belg; 1993 Sep; 61(3):21-3. PubMed ID: 8256682
[TBL] [Abstract][Full Text] [Related]
30. Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.
Halachmi S; Moskovitz B; Maffezzini M; Conti G; Verweij F; Kedar D; Sandri SD; Nativ O; Colombo R
Urol Oncol; 2011; 29(3):259-64. PubMed ID: 19395285
[TBL] [Abstract][Full Text] [Related]
31. [Oral tegafur plus mitomycin versus intravesical mitomycin alone in the prevention of recurrence in stage Ta bladder tumors].
Server Pastor G; Rigabert Montiel M; Bañón Pérez V; Valdelvira Nadal P; Cao Avellaneda E; García Hernández JA; Pérez Albacete M
Actas Urol Esp; 2003 Jun; 27(6):438-41. PubMed ID: 12918150
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term follow-up.
El-Ghobashy S; El-Leithy TR; Roshdy MM; El-Ganzoury HM
J Egypt Natl Canc Inst; 2007 Jun; 19(2):121-6. PubMed ID: 19034342
[TBL] [Abstract][Full Text] [Related]
33. Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy.
Freifeld Y; Ghandour R; Singla N; Woldu S; Bagrodia A; Lotan Y; Rapoport LM; Gazimiev M; Delafuente K; Kulangara R; Robyak H; Petros FG; Raman JD; Matin SF; Margulis V
Urol Oncol; 2020 Sep; 38(9):737.e11-737.e16. PubMed ID: 32641241
[TBL] [Abstract][Full Text] [Related]
34. [Study of the synergy of microwave hyperthermia/intravesical chemotherapy in the prevention of recurrences of superficial tumors of the bladder].
Mauroy B; Bonnal JL; Prevost B; Chive M; Lhotellier V; Sozanski JP; Vanseymortier L; Stefaniak X
Prog Urol; 1999 Feb; 9(1):69-80. PubMed ID: 10212955
[TBL] [Abstract][Full Text] [Related]
35. Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase.
Höbarth K; Maier U; Marberger M
Eur Urol; 1992; 21(3):206-10. PubMed ID: 1499626
[TBL] [Abstract][Full Text] [Related]
36. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C.
Racioppi M; Porreca A; Foschi N; Delicato G; Destito A; D'Addessi A
Urol Int; 2005; 75(4):373-5. PubMed ID: 16327311
[TBL] [Abstract][Full Text] [Related]
37. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Au JL; Badalament RA; Wientjes MG; Young DC; Warner JA; Venema PL; Pollifrone DL; Harbrecht JD; Chin JL; Lerner SP; Miles BJ;
J Natl Cancer Inst; 2001 Apr; 93(8):597-604. PubMed ID: 11309436
[TBL] [Abstract][Full Text] [Related]
38. [Prophylactic intravesical instillation therapy in patients with superficial bladder cancer--results of a randomized prospective study].
Tsushima T; Nasu Y; Abeki N; Noda M; Saika T; Ohmori H; Kobashi K; Ozaki Y; Matsumura Y; Tanahashi T
Nihon Hinyokika Gakkai Zasshi; 1992 Aug; 83(8):1314-21. PubMed ID: 1405170
[TBL] [Abstract][Full Text] [Related]
39. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design.
Zincke H; Benson RC; Hilton JF; Taylor WF
J Urol; 1985 Dec; 134(6):1110-4. PubMed ID: 3932685
[TBL] [Abstract][Full Text] [Related]
40. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
